Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1982 Mar;58(677):160–164. doi: 10.1136/pgmj.58.677.160

Treatment of small cell lung carcinoma in association with cryptogenic fibrosing alveolitis

J R Lipton, K Carroll, J J Mould, J Winstanley, N Thatcher
PMCID: PMC2426360  PMID: 6285324

Abstract

Two patients with small cell bronchogenic carcinoma associated with cryptogenic fibrosing alveolitis are described. Both patients received radiotherapy and i.v. chemotherapy with moderate dose methotrexate (100 mg/m2) and escalating high dose cyclophosphamide (1·5 g, 2·5 g, 3·5 g/m2).

Good symptomatic improvement was obtained with concurrent tumour response. No effect upon the alveolitis was observed. The pulmonary toxicity associated with methotrexate, cyclophosphamide chemotherapy and radiotherapy is described. The use of immunosuppressive agents (including cytotoxic drugs) to improve fibrosing alveolitis is also discussed

There is no apparent contraindication for intensive antitumour therapy in patients with small cell lung cancer and fibrosing alveolitis.

Full text

PDF
160

Images in this article

162Fig. 1
on p.162
163Fig. 2
on p.163

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Collis C. H. Lung damage from cytotoxic drugs. Cancer Chemother Pharmacol. 1980;4(1):17–27. doi: 10.1007/BF00255453. [DOI] [PubMed] [Google Scholar]
  2. Crystal R. G., Fulmer J. D., Roberts W. C., Moss M. L., Line B. R., Reynolds H. Y. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976 Dec;85(6):769–788. doi: 10.7326/0003-4819-85-6-769. [DOI] [PubMed] [Google Scholar]
  3. Deeley T. J. Review article. The treatment of carcinoma of the bronchus. Br J Radiol. 1967 Nov;40(479):801–822. doi: 10.1259/0007-1285-40-479-801. [DOI] [PubMed] [Google Scholar]
  4. Livingston R. B. Small cell carcinoma of the lung. Blood. 1980 Oct;56(4):575–584. [PubMed] [Google Scholar]
  5. Matthews M. J. Morphology of lung cancer. Semin Oncol. 1974 Sep;1(3):175–182. [PubMed] [Google Scholar]
  6. Phillips T. L., Fu K. K. Quantification of combined radiation therapy and chemotherapy effects on critical normal tissues. Cancer. 1976 Feb;37(2 Suppl):1186–1200. doi: 10.1002/1097-0142(197602)37:2+<1186::aid-cncr2820370830>3.0.co;2-v. [DOI] [PubMed] [Google Scholar]
  7. Plowman P. N., Stableforth D. E. Dermatomyositis with fibrosing alveolitis: response to treatment with cyclophosphamide. Proc R Soc Med. 1977 Oct;70(10):738–740. doi: 10.1177/003591577707001023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Stack B. H., Choo-Kang Y. F., Heard B. E. The prognosis of cryptogenic fibrosing alveolitis. Thorax. 1972 Sep;27(5):535–542. doi: 10.1136/thx.27.5.535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Turner-Warwick M., Lebowitz M., Burrows B., Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax. 1980 Jul;35(7):496–499. doi: 10.1136/thx.35.7.496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Willson J. K. Pulmonary toxicity of antineoplastic drugs. Cancer Treat Rep. 1978 Dec;62(12):2003–2008. [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES